Peregrine Pharma New (PPHM) 0.41 $PPHM
Peregrine Pharmaceuticals (PPHM) Q3 2016 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Mar 09, 10:25AM CST
PPHM: 0.41 (+0.01)
Peregrine Pharma reports FQ3 results
Seeking Alpha - at Seeking Alpha - Wed Mar 09, 8:14AM CST
PPHM: 0.41 (+0.01)
Peregrine Pharmaceuticals Reports Financial Results for Third Quarter of Fiscal Year 2016 and Recent Developments
GlobeNewswire - Wed Mar 09, 7:22AM CST
--Company Focused on Advancing Its Bavituximab Immuno-Oncology Program Through Its Pharmaceutical, Academic and Clinical Collaborations--
PPHMP: 17.99 (+0.15), PPHM: 0.41 (+0.01)
Peregrine reports 3Q loss
Automated Insights - Wed Mar 09, 7:13AM CST
TUSTIN, Calif. (AP) _ Peregrine Pharmaceuticals Inc. (PPHM) on Wednesday reported a loss of $16.8 million in its fiscal third quarter.
PPHM: 0.41 (+0.01)
Notable earnings before Wednesday’s open
Seeking Alpha - at Seeking Alpha - Tue Mar 08, 4:30PM CST
LGIH: 22.99 (-0.02), EXPR: 20.68 (-0.11), ONCE: 32.43 (-0.45), PPHM: 0.41 (+0.01), VRA: 19.76 (+1.14), AMED: 43.76 (+0.01), KFY: 28.00 (-0.43), HOV: 1.46 (-0.04), LMIA: 8.98 (+0.12)
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
GlobeNewswire - Mon Mar 07, 3:05PM CST
Peregrine Pharmaceuticals, Inc. (Nasdaq
PHM) (NasdaqPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock"
.
PPHMP: 17.99 (+0.15), PPHM: 0.41 (+0.01)
Peregrine Pharmaceuticals Announces Formal Commissioning of New, State-of-the-Art Commercial Manufacturing Facility
GlobeNewswire - Mon Mar 07, 7:05AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQPHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that its new state-of-the-art commercial biomanufacturing suite in Tustin, California, has been formally commissioned. As part of the commissioning process, all relevant regulatory agencies have been notified and cGMP production is currently underway. The new Peregrine facility, which is being operated by Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine, will more than double the company's prior manufacturing capacity, supporting up to an additional $40 million in revenue each year.
PPHMP: 17.99 (+0.15), PPHM: 0.41 (+0.01)
Peregrine to Report Financial Results for Third Quarter of Fiscal Year 2016 Prior to Market Open on March 9, 2016
GlobeNewswire - Thu Mar 03, 3:05PM CST
Peregrine Pharmaceuticals, Inc. (NASDAQPHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it will report financial results for the third quarter of fiscal year 2016 ended January 31, 2016 on March 9, 2016 prior to market open and will host a conference call and webcast at 8:30 AM Pacific Time (11:30 AM Eastern Time). Peregrine's senior management will discuss financial results for the third quarter and review the recent progress of its clinical development programs.
PPHMP: 17.99 (+0.15), PPHM: 0.41 (+0.01)
OncBioMune Patents a New Promising Approach to Chemotherapy
ACCESSWIRE - Thu Jan 28, 7:00AM CST
REDONDO BEACH, CA / ACCESSWIRE / January 28, 2016 / Chemotherapy compounds like paclitaxel and docetaxel have been used for years to treat cancer, but the caveat is that they indiscriminately kill both cancerous and normal cells. In order to solve this problem, researchers have tried a number of different approaches. The most common approach has been conjugating anti-cancer agents to antibodies or functional fragments, but even then, there are significant numbers of normal cells affected.
SGEN: 34.68 (+0.09), IMGN: 7.85 (+0.04), PPHM: 0.41 (+0.01), SRNE: 4.98 (+0.04), CELG: 100.54 (+0.62)
Peregrine Pharma (PPHM): Strong Industry, Solid Earnings Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Fri Jan 22, 7:43AM CST
Peregrine Pharma is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
PPHM: 0.41 (+0.01)
Peregrine Pharmaceuticals to Present at Two Upcoming Cancer Immunotherapy Conferences
GlobeNewswire - Wed Jan 20, 7:05AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQPHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that members of the company's scientific team will deliver podium presentations focused on the role of combination immunotherapies in the treatment of cancer at two upcoming immunotherapy conferences. Jeff T. Hutchins, Ph.D., Peregrine's vice president, preclinical research, will speak at Immunotherapy World 2016, being held January 25-27, 2016 in Washington, D.C. Additionally, Bruce Freimark, Ph.D., research director, preclinical oncology at Peregrine, will present at GTCBio's 8th Immunotherapeutics & Immunomonitoring Conference, being held January 25-26, 2016 in San Diego, CA.
PPHMP: 17.99 (+0.15), PPHM: 0.41 (+0.01)
Peregrine Pharmaceuticals Provides Update on Planned Expansion of Bavituximab Clinical Program in Lung, Breast and Other Cancers
GlobeNewswire - Mon Jan 11, 7:05AM CST
-- Phase II Study in NSCLC in Collaboration with AstraZeneca Evaluating Bavituximab Plus Durvalumab to Expand Lung Cancer Program in Q1 2016 --
PPHMP: 17.99 (+0.15), PPHM: 0.41 (+0.01)
Peregrine (PPHM) Inks Research Partnership for Bavituximab
Zacks Equity Research - Zacks Investment Research - Thu Jan 07, 1:00PM CST
Peregrine (PPHM) is collaborating with the National Comprehensive Cancer Network to evaluate bavituximab for the treatment of a range of tumors.
AZN: 28.00 (-0.01), HZNP: 16.02 (-0.30), PPHM: 0.41 (+0.01), SNY: 38.87 (-0.53)
Peregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration to Evaluate Novel Cancer Treatment Combinations With Bavituximab
GlobeNewswire - Wed Jan 06, 7:05AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQPHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced a new research collaboration with the National Comprehensive Cancer Network(R) (NCCN(R)) to expand the company's ongoing clinical research and development of bavituximab for the treatment of a range of tumors. NCCN, a not-for-profit alliance of 26 of the world's leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Peregrine will fund multiple investigator-initiated clinical and correlative studies with bavituximab in multiple cancers at NCCN Member Institutions and their affiliate community hospitals through a $2 million research grant to NCCN's Oncology Research Program (ORP). NCCN will be responsible for oversight and monitoring of the clinical studies through the research grant.
PPHMP: 17.99 (+0.15), PPHM: 0.41 (+0.01)
Surging Earnings Estimates Signal Good News for Peregrine Pharmaceuticals (PPHM)
Zacks Equity Research - Zacks Investment Research - Wed Dec 23, 7:46AM CST
Peregrine Pharmaceuticals has decent short-term momentum and is also seeing solid activity on the earnings estimate revision front as well.
PPHM: 0.41 (+0.01)
The Life Sciences Report Announces 19 Companies for the 2016 Small-Cap Biotech Watchlist
Marketwired - Tue Dec 22, 8:01AM CST
In advance of the Biotech Showcase 2016, The Life Sciences Report has once again solicited top analysts to provide the names of innovative biotech companies that investors should keep an eye on in the upcoming year.
CRMD: 2.38 (+0.02), PIRS: 1.93 (+0.17), AST: 4.57 (-0.08), PPHM: 0.41 (+0.01)
Why You Shouldn't Bet Against Peregrine Pharmaceuticals (PPHM) Stock
Zacks Equity Research - Zacks Investment Research - Tue Dec 22, 7:39AM CST
Peregrine Pharmaceuticals (PPHM) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
PPHM: 0.41 (+0.01)
Peregrine Pharmaceuticals (PPHM) Q3 2016 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Mar 09, 10:25AM CST
PPHM: 0.41 (+0.01)
Peregrine Pharma reports FQ3 results
Seeking Alpha - at Seeking Alpha - Wed Mar 09, 8:14AM CST
PPHM: 0.41 (+0.01)
Peregrine Pharmaceuticals Reports Financial Results for Third Quarter of Fiscal Year 2016 and Recent Developments
GlobeNewswire - Wed Mar 09, 7:22AM CST
--Company Focused on Advancing Its Bavituximab Immuno-Oncology Program Through Its Pharmaceutical, Academic and Clinical Collaborations--
PPHMP: 17.99 (+0.15), PPHM: 0.41 (+0.01)
Peregrine reports 3Q loss
Automated Insights - Wed Mar 09, 7:13AM CST
TUSTIN, Calif. (AP) _ Peregrine Pharmaceuticals Inc. (PPHM) on Wednesday reported a loss of $16.8 million in its fiscal third quarter.
PPHM: 0.41 (+0.01)
Notable earnings before Wednesday’s open
Seeking Alpha - at Seeking Alpha - Tue Mar 08, 4:30PM CST
LGIH: 22.99 (-0.02), EXPR: 20.68 (-0.11), ONCE: 32.43 (-0.45), PPHM: 0.41 (+0.01), VRA: 19.76 (+1.14), AMED: 43.76 (+0.01), KFY: 28.00 (-0.43), HOV: 1.46 (-0.04), LMIA: 8.98 (+0.12)
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
GlobeNewswire - Mon Mar 07, 3:05PM CST
Peregrine Pharmaceuticals, Inc. (Nasdaq
PHM) (NasdaqPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock". PPHMP: 17.99 (+0.15), PPHM: 0.41 (+0.01)
Peregrine Pharmaceuticals Announces Formal Commissioning of New, State-of-the-Art Commercial Manufacturing Facility
GlobeNewswire - Mon Mar 07, 7:05AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ
PHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that its new state-of-the-art commercial biomanufacturing suite in Tustin, California, has been formally commissioned. As part of the commissioning process, all relevant regulatory agencies have been notified and cGMP production is currently underway. The new Peregrine facility, which is being operated by Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine, will more than double the company's prior manufacturing capacity, supporting up to an additional $40 million in revenue each year. PPHMP: 17.99 (+0.15), PPHM: 0.41 (+0.01)
Peregrine to Report Financial Results for Third Quarter of Fiscal Year 2016 Prior to Market Open on March 9, 2016
GlobeNewswire - Thu Mar 03, 3:05PM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ
PHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it will report financial results for the third quarter of fiscal year 2016 ended January 31, 2016 on March 9, 2016 prior to market open and will host a conference call and webcast at 8:30 AM Pacific Time (11:30 AM Eastern Time). Peregrine's senior management will discuss financial results for the third quarter and review the recent progress of its clinical development programs. PPHMP: 17.99 (+0.15), PPHM: 0.41 (+0.01)
OncBioMune Patents a New Promising Approach to Chemotherapy
ACCESSWIRE - Thu Jan 28, 7:00AM CST
REDONDO BEACH, CA / ACCESSWIRE / January 28, 2016 / Chemotherapy compounds like paclitaxel and docetaxel have been used for years to treat cancer, but the caveat is that they indiscriminately kill both cancerous and normal cells. In order to solve this problem, researchers have tried a number of different approaches. The most common approach has been conjugating anti-cancer agents to antibodies or functional fragments, but even then, there are significant numbers of normal cells affected.
SGEN: 34.68 (+0.09), IMGN: 7.85 (+0.04), PPHM: 0.41 (+0.01), SRNE: 4.98 (+0.04), CELG: 100.54 (+0.62)
Peregrine Pharma (PPHM): Strong Industry, Solid Earnings Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Fri Jan 22, 7:43AM CST
Peregrine Pharma is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
PPHM: 0.41 (+0.01)
Peregrine Pharmaceuticals to Present at Two Upcoming Cancer Immunotherapy Conferences
GlobeNewswire - Wed Jan 20, 7:05AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ
PHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that members of the company's scientific team will deliver podium presentations focused on the role of combination immunotherapies in the treatment of cancer at two upcoming immunotherapy conferences. Jeff T. Hutchins, Ph.D., Peregrine's vice president, preclinical research, will speak at Immunotherapy World 2016, being held January 25-27, 2016 in Washington, D.C. Additionally, Bruce Freimark, Ph.D., research director, preclinical oncology at Peregrine, will present at GTCBio's 8th Immunotherapeutics & Immunomonitoring Conference, being held January 25-26, 2016 in San Diego, CA. PPHMP: 17.99 (+0.15), PPHM: 0.41 (+0.01)
Peregrine Pharmaceuticals Provides Update on Planned Expansion of Bavituximab Clinical Program in Lung, Breast and Other Cancers
GlobeNewswire - Mon Jan 11, 7:05AM CST
-- Phase II Study in NSCLC in Collaboration with AstraZeneca Evaluating Bavituximab Plus Durvalumab to Expand Lung Cancer Program in Q1 2016 --
PPHMP: 17.99 (+0.15), PPHM: 0.41 (+0.01)
Peregrine (PPHM) Inks Research Partnership for Bavituximab
Zacks Equity Research - Zacks Investment Research - Thu Jan 07, 1:00PM CST
Peregrine (PPHM) is collaborating with the National Comprehensive Cancer Network to evaluate bavituximab for the treatment of a range of tumors.
AZN: 28.00 (-0.01), HZNP: 16.02 (-0.30), PPHM: 0.41 (+0.01), SNY: 38.87 (-0.53)
Peregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration to Evaluate Novel Cancer Treatment Combinations With Bavituximab
GlobeNewswire - Wed Jan 06, 7:05AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ
PHM) (NASDAQPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced a new research collaboration with the National Comprehensive Cancer Network(R) (NCCN(R)) to expand the company's ongoing clinical research and development of bavituximab for the treatment of a range of tumors. NCCN, a not-for-profit alliance of 26 of the world's leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Peregrine will fund multiple investigator-initiated clinical and correlative studies with bavituximab in multiple cancers at NCCN Member Institutions and their affiliate community hospitals through a $2 million research grant to NCCN's Oncology Research Program (ORP). NCCN will be responsible for oversight and monitoring of the clinical studies through the research grant. PPHMP: 17.99 (+0.15), PPHM: 0.41 (+0.01)
Surging Earnings Estimates Signal Good News for Peregrine Pharmaceuticals (PPHM)
Zacks Equity Research - Zacks Investment Research - Wed Dec 23, 7:46AM CST
Peregrine Pharmaceuticals has decent short-term momentum and is also seeing solid activity on the earnings estimate revision front as well.
PPHM: 0.41 (+0.01)
The Life Sciences Report Announces 19 Companies for the 2016 Small-Cap Biotech Watchlist
Marketwired - Tue Dec 22, 8:01AM CST
In advance of the Biotech Showcase 2016, The Life Sciences Report has once again solicited top analysts to provide the names of innovative biotech companies that investors should keep an eye on in the upcoming year.
CRMD: 2.38 (+0.02), PIRS: 1.93 (+0.17), AST: 4.57 (-0.08), PPHM: 0.41 (+0.01)
Why You Shouldn't Bet Against Peregrine Pharmaceuticals (PPHM) Stock
Zacks Equity Research - Zacks Investment Research - Tue Dec 22, 7:39AM CST
Peregrine Pharmaceuticals (PPHM) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
PPHM: 0.41 (+0.01)
